Effect of omeprazole on the hypotensive efficacy of amlodipine depending on the genetic characteristics of patients
https://doi.org/10.21518/2079-701X-2018-16-124-129
Abstract
Features of anti-hypertensive therapy amlodipiny at patients with the arterial hypertonia (AH) with comorbid pathology – kislotozavisimy diseases (KZZ), accepting омепразол, depending on genetic features of the patient are studied and analysed. It is shown that a certain genetic polymorphism of an isoenzyme of P450 3A4 cytochrome can shift a metabolism of an omeprazol towards P450 3A4 cytochrome and promote more expressed oppression of activity of this enzyme. Depending on rate of a metabolism at the sick AG and KZZ receiving a combination of an amlodipin and an omeprazol various anti-hypertensive effect of an amlodipin can be observed. Reliable differences in dynamics of indicators of daily monitoring of the arterial blood pressure (ABP) at sick AG - slow metabolizator and sick AG – fast and intermediate metabolizator are received. Decrease of the activity of an isoenzyme of P450 3A4 cytochrome at patients - slow metabolizator leads to retardation of a metabolism of an amlodipin and, as a result, to rising of its concentration in a blood plasma that is clinically shown by more expressed anti-hypertensive effect.
About the Authors
M. N. Dorofeeva
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Zh. M. Sizova
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
E. V. Shikh
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
N. I. Lapidus
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
K. A. Ryzhikova
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
N. P. Denisenko
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
E. A. Grishina
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Khlynova OV, Tuev AV, Beresneva LN. The problem of comorbidity in the light of the cardiovascular system condition in patients with arterial hypertension and acid-dependent diseases. Kazansky Meditsinsky Zhurnal, 2013, 94(1): 80-85.
2. Sychev DA (ed.) Sosnovsky EE, Orekhov RE, Bordovsky SP. Polypragmasia in clinical practice. St. Petersburg, 2016.
3. Sychev DA, Muslimova OV, Gavrysyuk EV. Pharmacogenetic technologies of personalized medicine: optimization of the use of drugs. Terra Medica, 2011, 1: 4-9.
4. Clinical pharmacology: a textbook ed. by Kukes VG. 4th ed., updated and revised. Moscow: GEOTAR-Media, 2008: 229-230.
5. Shikh EV, Sychev DA. The safety of pantoprozole from the perspective of drug interaction. Rossiyskiy Zhurnal Gastroentero logii, Gepatologii i Kolonoproktologii (RZGGK), 2012, 22(5): 4-12.
6. Morozova TE, Sychev DA, Shekh NV. Pharmacogenetic approaches to predicting the efficacy and safety of amlodipine in patients with arterial hypertension. Lechashchy Vrach, 2016, 3: 77-82.
7. Ozawa S, Soyama A, Saeki M, FukushimaUesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J. Ethnic differences in genetic polymorphisms of CYP2 D6, CYP2 C19, CYP3 As and MDR1/ABCB1. Drug Metab Pharmacokinet, 2004, 19: 83–95.
8. Gardiner SJ, Begg EJ. Pharmacogenetics, DrugMetabolizing Enzymes, and Clinical Practice. Pharmacol Rev, 2006, 58: 521–590.
9. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology, 2000, 61: 174-183.
10. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors Basic. Clin Pharmacol Toxicol, 2004, 95: 2–8.
11. Kukes VG, Sychev DA, Shikh EV. The role of drug biotransformation studies in increasing the effectiveness and safety of pharmacotherapy. Vrach, 2007, 1: 23-27.
12. Ivashkin VT, Maev IV, Sheptulin AA. Clinical guidelines of the Russian Gastroenterological Association for diagnosis and treatment of gastroesophageal reflux disease. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii i Kolonoproktologii, 2017, 27(3): 75-95.
13. Denisenko NP, Sychev DA, Sizova ZhM. High prevalence of fast metabolizers in CYP 2S19 among Russian patients with peptic ulcer. Eksperimentalnaya i Klinicheskaya Gastroenterologiya, 2015, 118(6): 11-15.
14. Klyaritskaya IL, Rabotyagova YuS. Polymorphism of the cytochrome CYP2C19 gene and the clinical significance of its identification. 2013 Krymskiy Terapevticheskiy Zhurnal, 2013, 1: 19-25.
15. Peredery VG, Tkach SM, Klimenko. Clinical significance of genetic polymorphism CYP2C19 on the example of the metabolism of PPI. Zdorovya Ukrainy, 2011: 14-16.
16. Morozova TE, Sychev DA, Shikh NV. Pharmacogenetic approaches to predicting the efficacy and safety of pharmacotherapy of arterial hypertension. Lechashchy Vrach, 2016, 3.
17. Kairbekov A, Eralieva BA, Kiyokova BKh., Bayzhigitova NB, Ordakhanova MS, Tastemirova KК, Kudabaev VZh. Treatment of hypertension in elderly patients with chronic cerebral ischemia. Vestnik KazNMU, 2017, 3: 41-42.
18. Shevchenko OV, Bychkov YeN, Posnenkova OM, Meaning of pharmacogenetic studies for optimization of antihypertensive therapy. Vestnik RUDN, Meditsina series, 2012, 3: 95-100.
Review
For citations:
Dorofeeva MN, Sizova ZM, Shikh EV, Lapidus NI, Ryzhikova KA, Denisenko NP, Grishina EA, Sychev DA. Effect of omeprazole on the hypotensive efficacy of amlodipine depending on the genetic characteristics of patients. Meditsinskiy sovet = Medical Council. 2018;(16):124-129. (In Russ.) https://doi.org/10.21518/2079-701X-2018-16-124-129
Views:
7452
Email this article 